最新临床试验：马来酸西地拉尼和奥拉帕尼或标准化疗治疗复发性铂耐药或难治性卵巢、输卵管或原发性腹膜癌患者

这是经美国国家癌症研究所批准的一项多中心随机对照 II / III期临床试验，目的是研究马来酸西地拉尼和奥拉帕尼是否联用对治疗卵巢、输卵管或原发性腹膜癌患者的效果，这些患者均为接受铂类治疗后复发（铂耐药）或接受以铂为基础的化疗后仍持续增长(铂难治性)，并与标准化疗进行比较。马来酸西地拉尼和奥拉帕尼可能通过阻断细胞生长所需的酶来阻止肿瘤细胞的生长。化疗中使用的药物以不同的方式阻止肿瘤细胞的生长，或杀死细胞，或阻止细胞分裂，或阻止细胞扩散。目前还不清楚与单独用药或标准化疗相比，马来酸西地拉尼布和奥拉帕尼联合用药是否会对癌细胞造成更大的杀伤力。

该临床试验在全美305家医院进行开展。

This randomized phase II / III trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has returned after receiving chemotherapy with drugs that contain platinum (platinum-resistant) or continued to grow while being treated with platinum-based chemotherapy drugs (platinum-refractory). Cediranib maleate and olaparib may stop the growth of tumor cells by blocking enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cediranib maleate and olaparib together may cause more damage to cancer cells when compared to either drug alone or standard chemotherapy.

Trial IDs